Mari Kyllesø Halles bilde

Mari Kyllesø Halle

  • E-postmari.halle@uib.no
  • Besøksadresse
    Jonas Lies vei 72
    5053 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

I hold a PhD from the University of Bergen on molecular alterations suggesting new treatment strategies in uterine carcinomas. I am currently a researcher in the Bergen Gynecological Cancer Research Group, working on gynecological cancer. My main focus is to characterize targetable molecular alterations driving aggressive uterine carcinoma. Currently, I am working on a study comparing radiomic features from whole tumor segmented magnetic resonance imaging (MRI) scans to genomic profiles. This radiogenomic approach will detect novel prognosticators for disease outcome and may reveal new treatment strategies in cervical cancer.

Vitenskapelig artikkel
  • Vis forfatter(e) (2022). What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer? Insight into Imaging. 1-14.
  • Vis forfatter(e) (2022). Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. British Journal of Cancer. 9 sider.
  • Vis forfatter(e) (2022). Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology. 6444-6455.
  • Vis forfatter(e) (2022). Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. Nature Communications. 1-17.
  • Vis forfatter(e) (2022). Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers. 1-16.
  • Vis forfatter(e) (2022). APOBEC3A/B deletion polymorphism and endometrial cancer risk. Cancer Medicine.
  • Vis forfatter(e) (2021). Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. Biomarkers. 302-308.
  • Vis forfatter(e) (2021). High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences. 17 sider.
  • Vis forfatter(e) (2021). Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers. 15 sider.
  • Vis forfatter(e) (2021). Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. NPJ GENOMIC MEDICINE.
  • Vis forfatter(e) (2021). A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology. 12 sider.
  • Vis forfatter(e) (2021). A gene signature identifying CIN3 regression and cervical cancer survival. Cancers. 1-18.
  • Vis forfatter(e) (2021). A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer. 1690-1698.
  • Vis forfatter(e) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Vis forfatter(e) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Vis forfatter(e) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Vis forfatter(e) (2019). PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Vis forfatter(e) (2019). Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Vis forfatter(e) (2019). Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Vis forfatter(e) (2018). The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging. 1-14.
  • Vis forfatter(e) (2018). Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Vis forfatter(e) (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Vis forfatter(e) (2017). PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Vis forfatter(e) (2017). MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer. 1-6.
  • Vis forfatter(e) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Vis forfatter(e) (2017). Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Vis forfatter(e) (2017). Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Vis forfatter(e) (2016). Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Vis forfatter(e) (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Vis forfatter(e) (2016). The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumour Biology. 10697-10702.
  • Vis forfatter(e) (2016). Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 513-523.
  • Vis forfatter(e) (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Vis forfatter(e) (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Vis forfatter(e) (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Vis forfatter(e) (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Vis forfatter(e) (2014). The evolution and functional divergence of the beta-carotene oxygenase gene family in teleost fish-Exemplified by Atlantic salmon. Gene. 268-274.
  • Vis forfatter(e) (2014). Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Vis forfatter(e) (2014). Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Vis forfatter(e) (2014). Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Vis forfatter(e) (2014). Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • Vis forfatter(e) (2014). Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Vis forfatter(e) (2014). Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Vis forfatter(e) (2014). Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Vis forfatter(e) (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Vis forfatter(e) (2014). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Vis forfatter(e) (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Vis forfatter(e) (2013). Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Vis forfatter(e) (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 sider.
  • Vis forfatter(e) (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Vis forfatter(e) (2012). High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Vis forfatter(e) (2012). Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
  • Vis forfatter(e) (2012). Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
  • Vis forfatter(e) (2017). Molecular alterations suggesting new treatment strategies in uterine carcinomas.

Se fullstendig oversikt over publikasjoner i CRIStin.